Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIDE: Isotoxic dose-escalated radiochemotherapy plus bevacizumab in newly diagnosed IDH-wildtype, MGMT-unmethylated glioblastoma
2021-000565-32Phase 2Active
- Sponsor
- LMU Klinikum
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in glioblastoma (GBM), sponsored by LMU Klinikum. Primary endpoint: Overall survival after 2 years. Started Jan 2023; status: active.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2021-000565-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000565-32.